Maxigesic to launch in Canada in 2020

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969







Market and Media Release 26 November 2019

Maxigesic to launch in Canada in 2020

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) and Canadian speciality pharmaceutical company
Biosyent Pharma Inc., today announce they have concluded an exclusive licensing and
supply agreement that will see the launch of the Maxigesic pain relief medicine in Canada
next year.
The agreement follows Health Canada’s recent approval of the tablet form of Maxigesic
(known locally as Combogesic®), the first paracetamol and ibuprofen combination to be
approved in Canada.
Under the agreement, BioSyent Pharma Inc. also has rights to additional forms of
Maxigesic®/Combogesic® in Canada, where the market for analgesics is worth CAD$813
million
1
. Other forms include an oral liquid for paediatric use and an intravenous formulation
for hospital use, both of which will require regulatory approval.
AFT Pharmaceuticals Chief Executive Dr Hartley Atkinson said: “This agreement, which will see
Biosyent Pharma distribute the medication under AFT’s Combogesic® brand, paves the way
for the Maxigesic platform to make its first entry into a North American market. It is an exciting
opportunity for both companies.”
President and CEO of BioSyent, René Goehrum said: “We are pleased to add
Maxigesic®/Combogesic® to our product portfolio and look forward to making this medicine
available to Canadians.
“The management of pain continues to be a challenge for healthcare practitioners and
patients, and we believe Maxigesic/Combogesic® will provide clinically-proven double-
action relief from a wide range of pain. Combining oral analgesics into a single product
improves compliance, safety and efficacy.”
For more information:
Investors Media:
Hartley Atkinson, CEO Richard Inder
AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: +64 21 645 643
Email: hartley@aftpharm.com Email: richard@theproject.co.nz





1
IQVIA CDH June 2019. Total analgesic market in the year to the end of June 2019.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969


About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical business with a broad range of products, both
developed itself and in-licensed from third parties. AFT’s products cover all major
pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically,
AFT’s home markets have been Australia, New Zealand and South-East Asia. However, the
company is out-licensing its own products to licensees and distributors to sell in an increasing
number of countries around the world. The company’s intensive Research and Development
programme forms the basis of its international sales strategy. For more information about the
company, visit our website www.aftpharm.com
.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable
growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring
innovative pharmaceutical and other healthcare products that have been successfully
developed, are safe and effective, and have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that treat these patients by marketing
its products through its community, hospital and international business units.